Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 8, 2016, Pages 903-906

  Schweizer, M T ^a,b   Plymate, S R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Androgen receptor; drug resistance; prostate cancer; splice variants

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTINEOPLASTIC AGENT; ISOPROTEIN; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DRUG TARGETING; EDITORIAL; HUMAN; MALE; NUCLEAR LOCALIZATION SIGNAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; ORCHIECTOMY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84961393063     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1159676     Document Type: Editorial

References (30)

1. P.L.Shaffer, A.Jivan, D.E.Dollins, et al. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A. 2004;101:4758–4763.
2. M.T.Schweizer, E.Y.Yu Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8:128.
3. D.Robinson, E.M.Van Allen, Y.-M.Wu, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228.
4. R.Kumar, I.J.McEwan. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev. 2012;33:271–299.
5. Y.Li, M.Alsagabi, D.Fan, et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011;71:2108–2117.
6. L.L.Liu, N.Xie, S.Sun, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014;33:3140–3150.
7. Z.Yu, S.Chen, A.G.Sowalsky, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20:1590–1600.
8. S.C.Chan, L.A.Selth, Y.Li, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015;43:5880–5897.
9. R.Hu, C.Lu, E.A.Mostaghel, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72:3457–3462.
10. E.S.Antonarakis, C.Lu, H.Wang, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038.
11. G.Liu, A.Li, S.Sun, et al. Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia (PA): AACR. Cancer Res. 2015;75(15 Suppl). Abstract no. 5159.
12. E.Efstathiou, M.Titus, S.Wen, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67:53–60.
13. P.A.Watson, Y.F.Chen, M.D.Balbas, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010;107:16759–16765.
14. E.A.Mostaghel, B.T.Marck, S.R.Plymate, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913–5925.
15. S.M.Dehm, L.J.Schmidt, H.V.Heemers, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469–5477.
16. Z.Guo, X.Yang, F.Sun, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–2313.
17. R.Hu, T.A.Dunn, S.Wei, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22.
18. S.Sun, C.C.T.Sprenger, R.L.Vessella, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715–2730.
19. D.Xu, Y.Zhan, Y.Qi, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res. 2015;75:3663–3671.
20. Y.Li, S.C.Chan, L.J.Brand, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–489.
21. J.-K.Myung, C.A.Banuelos, J.G.Fernandez, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123:2948–2960.
22. H.Li, F.Ban, K.Dalal, et al. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor. J Med Chem. 2014;57:6458–6467.
23. S.Yamashita, K.-P.Lai, K.-L.Chuang, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia. 2012;14:74–83.
24. Z.Yu, C.Cai, S.Gao, et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014;20:4075–4085.
25. C.Liu, W.Lou, Y.Zhu, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198–3210.
26. I.A.Asangani, K.Wilder-Romans, V.L.Dommeti, et al. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res. 2016. [Epub ahead of print].
27. L.R.Bohrer, P.Liu, J.Zhong, et al. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate. 2013;73:1017–1027.
28. N.Nadiminty, R.Tummala, C.Liu, et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12:1629–1637.
29. S.O.Peacock, C.D.Fahrenholtz, K.L.Burnstein. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol. 2012;26:1967–1979.
30. S.N.Mediwala, H.Sun, A.T.Szafran, et al. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate. 2013;73:267–277.